Irrus Investments

Novus Diagnostics is focused on developing an innovative diagnostic device aimed at detecting sepsis. This technology allows for the rapid and automated identification of pathogens present in whole blood samples. By providing results in minutes, Novus Diagnostics empowers healthcare providers to initiate effective treatment for sepsis patients quickly and efficiently. The approach not only enhances patient care but also aims to reduce costs associated with sepsis management.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Bounce Insights is a digital consumer research platform that connects brands directly with engaged consumers through its mobile app. The company specializes in delivering fast and robust quantitative research, offering a unique combination of research consultancy, data, and technology. By facilitating real-time access to consumer insights, Bounce Insights supports brands in their decision-making processes. Its clientele primarily includes companies in the consumer packaged goods, fast-moving consumer goods, and retail sectors, such as Diageo, Coca-Cola, and Tesco. Additionally, Bounce Insights collaborates with various media and advertising agencies, as well as firms in financial services, telecommunications, and e-commerce, enabling them to obtain the consumer insights necessary for informed decision-making.

Ovagen is a biotechnology company specializing in the production of germ-free (GF) chicken eggs and GF birds in commercial quantities, primarily for the pharmaceutical industry. The company has developed a unique process that enables large-scale production of recombinant proteins to Good Manufacturing Practice (GMP) standards using a transgenic chicken platform. This innovative approach provides pharmaceutical companies with a biosecure, flexible, and cost-effective biomanufacturing solution for vaccines and therapeutic proteins. In addition to its core production capabilities, Ovagen offers Contract Research Services and possesses extensive expertise in specific poultry and rodent research technologies, as well as in the housing and husbandry of specific pathogen-free (SPF) poultry and rodents.

SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.

FeelTect is a medical device company based in Galway, Ireland, founded in 2019. The company specializes in developing connected-health technology, specifically a pressure sensing device known as Tight Alright. This device is designed to measure and monitor sub-bandage pressure during compression therapy, which is crucial for treating venous leg ulcers (VLUs). Effective compression is essential; if the pressure is too loose, it fails to provide therapeutic benefits, while excessive pressure can pose serious risks. FeelTect's technology enables users to view live readings and recorded data, facilitating optimal and individualized treatment regimens. By improving the application and maintenance of safe sub-bandage pressure, FeelTect aims to enhance patient outcomes and reduce the associated health-economic burden.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovation aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant global market given the high prevalence of diabetic foot ulcers.

ByoWave is a company that specializes in creating inclusive gaming experiences through its innovative video game controller, the Proteus Controller. This modular controller is designed to accommodate both disabled and non-disabled gamers, featuring a unique 'snap and play' system that allows users to easily connect various components. ByoWave's approach enables gamers to customize their controller configurations online, facilitating sharing and collaboration within the gaming community. The Proteus Controller is compatible with popular gaming platforms, including Xbox and PC, ensuring a versatile solution for a diverse audience.

Ovagen is a biotechnology company specializing in the production of germ-free (GF) chicken eggs and GF birds in commercial quantities, primarily for the pharmaceutical industry. The company has developed a unique process that enables large-scale production of recombinant proteins to Good Manufacturing Practice (GMP) standards using a transgenic chicken platform. This innovative approach provides pharmaceutical companies with a biosecure, flexible, and cost-effective biomanufacturing solution for vaccines and therapeutic proteins. In addition to its core production capabilities, Ovagen offers Contract Research Services and possesses extensive expertise in specific poultry and rodent research technologies, as well as in the housing and husbandry of specific pathogen-free (SPF) poultry and rodents.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

Cinclus Pharma AG is a research-based biotech company focused on developing small molecules to treat gastric acid-related diseases, with a particular emphasis on gastroesophageal reflux disease (GERD). Their primary asset, X842, is designed to address severe erosive GERD and has undergone Phase I clinical trials. Additionally, the company is exploring a dual therapy treatment that combines an antibiotic targeting Helicobacter pylori bacteria. Cinclus Pharma AG operates from its headquarters in Basel, Switzerland.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Gasgon Medical is a medical device company focused on enhancing intravenous (IV) infusion processes. It aims to improve patient safety and clinical efficiency by developing innovative devices that minimize risks such as Vascular Air Embolism. By supporting medical staff with better tools, Gasgon enables them to deliver superior patient care and outcomes.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovation aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant global market given the high prevalence of diabetic foot ulcers.

Using the latest in-house technology Allview Healthcare gives you access to leading Consultant and surgical services Rapid diagnosis and care. Currently the largest dermatology provider across Ireland, servicing both the HSE (State Health Provider) and the VHI (Ireland's largest private insurance company) A highly experienced management team and board of directors with both medical and technical professionals whose main aim is to ensure that patients receive the best care by the best consultant at the right time. We work hard to ensure our best practice, clinical governance and quality assurance is at its highest level thus leading to extremely high patient satisfaction.

Sigrid Therapeutics AB is a clinical-stage biotechnology company based in Stockholm, Sweden, focused on developing innovative therapeutic products aimed at preventing and treating lifestyle diseases. The company has created a novel materials platform designed to alter food digestion in the body. Its lead product is an ingested medical device intended to lower blood sugar levels in prediabetics, representing a new approach to managing chronic conditions related to modern lifestyles. By targeting the gut, Sigrid Therapeutics seeks to help individuals achieve weight loss and overall better health outcomes.

AniV8 is a company focused on developing clinical sensor technology aimed at diagnosing and monitoring diseases in companion animals. Its innovative technology utilizes clinical data in conjunction with a unique algorithm to assess motion, allowing veterinarians to evaluate the impact of osteoarthritis pain in pets. By providing a reliable method for monitoring common disease states, AniV8 enhances the ability of veterinary professionals to deliver effective care for animals.

Qualus is a company focused on providing sustainable solutions for the leather industry, aiming to minimize the environmental impact of leather tanneries. The firm has developed a technology that utilizes small polymer granules known as Sferes, which assist tanneries in conserving water, lowering production costs, and enhancing the quality of leather products. By implementing this technology, Qualus enables its clients to reduce their energy consumption and carbon emissions, contributing to a more eco-friendly leather production process. The company has recently secured £3 million in financing to further advance its sustainable initiatives.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

CroiValve Limited, founded in 2016 and based in Dublin, Ireland, specializes in the development of a medical device aimed at treating severe tricuspid regurgitation through a minimally invasive procedure. The company's innovative device allows for percutaneous delivery via a vein into the right heart, effectively sealing the gap between the native tricuspid valve leaflets. This approach restores proper valve function and prevents regurgitation, enabling healthcare professionals to address this condition in a safe, effective, and cost-efficient manner. CroiValve's solution is designed to be user-friendly, catering to a broad range of patients suffering from this serious heart issue.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications that leverage artificial intelligence to enhance diagnostic workflows. The company offers two primary platforms: Diagnexia, which facilitates rapid diagnostics by connecting global subspecialty pathologists to address backlogs, and Patholytix Preclinical, designed for optimizing preclinical safety assessments in pharmaceutical research. By automating routine tasks and triaging high-volume, low-complexity samples, Deciphex enables pathologists to concentrate on more complex cases, ultimately improving productivity and patient outcomes. Through its innovative approach, Deciphex is committed to advancing healthcare delivery and therapeutic development.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

ProVerum Medical is a medtech company focused on developing innovative minimally invasive devices for the treatment of benign prostatic hyperplasia (BPH). The company's technology offers a safer and more patient-friendly alternative to traditional BPH treatments, allowing patients to receive care in either a doctor's office or an operating room. ProVerum's device is designed to address the symptoms of prostate enlargement, which can lead to difficulties in urination. By placing the device inside the urethra, it aims to restore normal urinary function, ultimately enabling healthcare providers to deliver effective treatment options for patients suffering from this condition.

OncoMark Limited, founded in 2007 and based in Dublin, Ireland, specializes in the discovery and development of diagnostics and therapeutic targets for cancer patients. As a spin-out from University College Dublin, the company focuses on creating companion diagnostic tests that enhance patient stratification in cancer drug development. These tests aid pharmaceutical companies in identifying patients for whom specific drugs are most likely to be effective, thereby improving clinical trial efficiency and success rates. OncoMark's portfolio includes tissue-based biomarker assays and a Biomarker Interpretation Workflow platform that automates various analyses, such as survival assessments and interpretation of immunohistochemistry staining. The company's diagnostic tests cover major cancer types, including breast, colorectal, prostate, and melanoma, and are supported by significant EU research and development funding. Led by CEO Dr. Mairin Rafferty, OncoMark is committed to improving treatment outcomes and quality of life for cancer patients.

ProVerum Medical is a medtech company focused on developing innovative minimally invasive devices for the treatment of benign prostatic hyperplasia (BPH). The company's technology offers a safer and more patient-friendly alternative to traditional BPH treatments, allowing patients to receive care in either a doctor's office or an operating room. ProVerum's device is designed to address the symptoms of prostate enlargement, which can lead to difficulties in urination. By placing the device inside the urethra, it aims to restore normal urinary function, ultimately enabling healthcare providers to deliver effective treatment options for patients suffering from this condition.

Adama Innovations Ltd. is a company based in Dublin, Ireland, focused on developing nanotechnology solutions for advanced manufacturing. Established in 2010 as a spin-out from the CRANN nanotechnology institute at Trinity College Dublin, Adama Innovations specializes in creating high-resolution nanoscale probes fabricated from diamond. These probes are designed for use in atomic force microscopy, enabling precise imaging, measurement, and manipulation at the nanoscale. The company’s innovative technology allows for the creation of micro-patterns on ultra-hard materials, which can be applied in various industries, including medical device fabrication, labeling, and anti-counterfeiting. Additionally, Adama Innovations offers a range of products, including diamond sharp cones and flare-shaped probes, to enhance capabilities in metrology and precision engineering.

Embo Medical, located at the National University of Ireland, is focused on developing innovative medical devices for vascular embolization. The company is creating the Caterpillar, a groundbreaking one-shot embolization device designed to enhance the efficiency and safety of peripheral vascular embolization procedures. This device aims to significantly reduce procedural times, enabling physicians to perform embolizations in a more cost-effective manner. With approximately 180,000 such procedures conducted annually worldwide, Embo Medical is positioned to make a meaningful impact in the medical field by improving patient outcomes and streamlining medical practices.

Wattics is a Dublin-based company that specializes in energy analytics software aimed at combating climate change. The firm provides a cloud-based data analytics and business intelligence platform tailored for energy consultants, analysts, and managers. By transforming traditional methods of energy management, Wattics enables users to move beyond static spreadsheets to dynamic, actionable insights that facilitate better cost control and asset management. The platform offers compatibility with various meter manufacturers, renewable energy sources, environmental sensors, and IoT devices, featuring advanced machine learning to detect energy abnormalities. Wattics' services include the COMPOSER and MAESTRO plans, which allow energy professionals to create custom formulas for energy efficiency projects and fully brand their analytics services. This innovative approach helps users acquire and retain customers through detailed saving and insight reports, ultimately creating new revenue streams. Founded in 2011 by Antonio Ruzzelli, Wattics has expanded its support operations to New York, Treviso, and Berlin, enhancing its global reach in the energy management market.